Trifluridine/tipiracil (FTD/TPI) and regorafenib in older patients with metastatic colorectal cancer

Ana Paula Ornellas S Victorino; Fernando Meton; Luciana Mardegan; Juliana Festa; Diogo N Piranda; Kelly Borges Araujo

doi:10.1016/j.jgo.2023.101477

Trifluridine/tipiracil (FTD/TPI) and regorafenib in older patients with metastatic colorectal cancer

J Geriatr Oncol. 2023 May;14(4):101477. doi: 10.1016/j.jgo.2023.101477. Epub 2023 Mar 27.

Authors

Ana Paula Ornellas S Victorino¹, Fernando Meton¹, Luciana Mardegan², Juliana Festa², Diogo N Piranda², Kelly Borges Araujo³

Affiliations

¹ Americas Oncologia, RJ, Brazil.
² Laboratórios Servier do Brazil, RJ, Brazil.
³ Americas Oncologia, RJ, Brazil. Electronic address: [email protected].

PMID: 36990929
DOI: 10.1016/j.jgo.2023.101477

Abstract

Colorectal cancer is a disease of older patients, but few guidelines directly address age in their recommendations. Older patients may present comorbidities that affect the choice of chemotherapy, and care must be taken when choosing the best approach. This narrative review aimed to describe the literature regarding approved oral agents for third-line treatment in older patients with refractory metastatic colorectal cancer, regorafenib, and trifluridine/tipiracil (FTD/TPI).

Keywords: Chemotherapy; FTD/TPI; Metastatic colorectal cancer; Older people; Regorafenib.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Aged
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Colonic Neoplasms* / drug therapy
Colorectal Neoplasms* / drug therapy
Colorectal Neoplasms* / pathology
Frontotemporal Dementia* / drug therapy
Humans
Rectal Neoplasms* / drug therapy
Trifluridine / therapeutic use
Uracil / therapeutic use

Substances

tipiracil
Trifluridine
regorafenib
Uracil